Fed Governor Cook sues Trump over firing attempt
Haleon plc (LSE/NYSE:HLN), a leader in the consumer health industry, disclosed a transaction by a Person Discharging Managerial Responsibilities (PDMR) in a recent SEC filing. On Monday, the company reported that Bláthnaid Bergin, an Independent (LON:IOG) Non-Executive Director and PDMR, purchased ordinary shares.
The transaction took place on Thursday, involving the acquisition of 6,145 Haleon ordinary shares at a price of £4.0427 per share. This purchase was conducted on the London Stock Exchange (LON:LSEG) (XLON). The company provided the identification code for the shares as GB00BMX86B70.
The filing stated that this was an initial notification and did not aggregate with any other transactions. It was a single transaction with no further aggregated information provided. The disclosure aligns with the UK Market Abuse Regulation requirements, ensuring transparency in transactions by company insiders.
Haleon’s portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren. The company focuses on products across six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other.
This financial activity comes as part of the company’s commitment to transparency and regulatory compliance, as detailed in the SEC Form 6-K. The filing was signed by Amanda Mellor, Company Secretary, on behalf of Haleon plc. The information is based on a press release statement and reflects the company’s adherence to legal reporting standards.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.